Recurrent hemorrhage from corpus luteum during anticoagulant therapy. 1977

K P Wong, and P G Gillett

A 43-year old woman had recurrent massive intraperitoneal hemorrhage from rupture of a hemorrhagic corpus luteum in two successive menstrual cycles while receiving anticoagulant therapy. Left oophorectomy was performed on the first occasion and right salpingo-oophorectomy with left salpingectomy on the second. While the precise incidence cannot be determined, rupture from a hemorrhagic corpus luteum appears to be a rare but potentially catastrophic complication of anticoagulant therapy. Hence possible ovarian hemorrhage should be considered in women of reproductive age receiving heparin or sodium warfarin therapy.

UI MeSH Term Description Entries
D010049 Ovarian Diseases Pathological processes of the OVARY. Disease, Ovarian,Diseases, Ovarian,Ovarian Disease
D003338 Corpus Luteum The yellow body derived from the ruptured OVARIAN FOLLICLE after OVULATION. The process of corpus luteum formation, LUTEINIZATION, is regulated by LUTEINIZING HORMONE. Corpora Lutea,Lutea, Corpora
D005260 Female Females
D006470 Hemorrhage Bleeding or escape of blood from a vessel. Bleeding,Hemorrhages
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D012422 Rupture, Spontaneous Tear or break of an organ, vessel or other soft part of the body, occurring in the absence of external force. Ruptures, Spontaneous,Spontaneous Rupture,Spontaneous Ruptures
D014859 Warfarin An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide. 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one,Aldocumar,Apo-Warfarin,Coumadin,Coumadine,Gen-Warfarin,Marevan,Tedicumar,Warfant,Warfarin Potassium,Warfarin Sodium,Potassium, Warfarin,Sodium, Warfarin

Related Publications

K P Wong, and P G Gillett
May 1971, Obstetrics and gynecology,
K P Wong, and P G Gillett
September 1976, Southern medical journal,
K P Wong, and P G Gillett
May 1978, Annals of internal medicine,
K P Wong, and P G Gillett
December 1980, The West Virginia medical journal,
K P Wong, and P G Gillett
March 2002, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
K P Wong, and P G Gillett
January 1949, Rivista d'ostetricia e ginecologia pratica,
K P Wong, and P G Gillett
July 1956, Zentralblatt fur Gynakologie,
K P Wong, and P G Gillett
January 1955, Zentralblatt fur Gynakologie,
Copied contents to your clipboard!